Cancer
Malignant Kidney Neoplasm
CI-CAN-00003171Explore in graph →
Top-level453 active trials17 approved drugs80 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003171Explore in graph →
Clinical trials
2,143 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (339)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01002937 | Novel Prognostic Markers in Renal Cancer | completed | — | 182 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT04518046 | Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies | completed | Phase 1 | 22 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jun 5, 2024 | clinicaltrials |
| NCT03776123 | Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients | completed | — | 347 | IpsenINDUSTRY | 1 | May 29, 2024 | clinicaltrials |
| NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | completed | Phase 1 | 48 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT04752267 | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases | completed | Early Phase 1 | 10 | University of Southern CaliforniaOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT04604158 | Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients | completed | N/A | 38 | Gillian GreshamOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT03849118 | 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study(89ZR-TLX250) | completed | Phase 3 | 300 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 8 | May 17, 2024 | clinicaltrials |
| NCT00831857 | VEGF Imaging in Renal Cell Carcinoma(Renimage) | completed | — | 26 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT00970970 | Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease(VHLimage) | completed | — | 22 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT01028638 | Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell Carcinoma(Everolimage) | completed | — | 13 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT01398306 | Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.(BANN) | completed | — | 40 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT03097328 | Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma | completed | Phase 2 | 39 | Bradley A. McGregor, MDOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT01931644 | At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions | completed | — | 17,667 | Sanguine BiosciencesINDUSTRY | 1 | Apr 18, 2024 | clinicaltrials |
| NCT06369519 | Optimization of Management for Sporadic Bilateral Renal Cell Carcinoma | completed | — | 3,677 | Peking University First HospitalOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | completed | Phase 1 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT05375136 | A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients | completed | — | 135 | Eisai Korea Inc.INDUSTRY | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06317207 | Evaluation of the Safety of Reoperation for Ipsilateral Recurrent Tumors After Nephron-sparing Partial Nephrectomy(LiangAH) | completed | — | 15 | The First Affiliated Hospital of Anhui Medical UniversityOTHER | 0 | Mar 19, 2024 | clinicaltrials |
| NCT02762006 | Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma | completed | Phase 1 | 29 | Moshe OrnsteinOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT03126331 | Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab | completed | Phase 2 | 26 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT06214000 | Primary Care-Based Follow-up of Cancer Survivors of the Prostate and Kidney(LiVHOU) | completed | — | 178 | University Hospital, Strasbourg, FranceOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT02156895 | Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea | completed | — | 111 | PfizerINDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT04834778 | A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) | completed | Phase 1 | 23 | HiberCell, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT02527304 | Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery | completed | N/A | 24 | Albert Einstein College of MedicineOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT00019396 | flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT00019539 | Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03012581 | Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types(AcSé) | completed | Phase 2 | 269 | UNICANCEROTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04540705 | A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread(PIVOT IO 011) | completed | Phase 1 | 30 | Bristol-Myers SquibbINDUSTRY | 8 | Feb 28, 2024 | clinicaltrials |
| NCT02944617 | Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor | completed | N/A | 21 | City of Hope Medical CenterOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT03511391 | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors(CHEERS) | completed | Phase 2 | 99 | University Hospital, GhentOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT03454451 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | completed | Phase 1 | 117 | Corvus Pharmaceuticals, Inc.INDUSTRY | 2 | Dec 21, 2023 | clinicaltrials |
| NCT04535921 | Fear of Cancer Recurrence in Genitourinary Cancer | completed | — | 500 | Ludwig-Maximilians - University of MunichOTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT05861778 | Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma(ZIRDOSE-CP) | completed | Phase 1 | 10 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | Dec 11, 2023 | clinicaltrials |
| NCT03229278 | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | completed | Phase 1 | 14 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT00606866 | MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma(MRI) | completed | Phase 3 | 57 | University of ChicagoOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT02599324 | Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | completed | Phase 1 / Phase 2 | 263 | Pharmacyclics LLC.INDUSTRY | 4 | Nov 18, 2023 | clinicaltrials |
| NCT02498665 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | completed | Phase 1 | 24 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT04021238 | Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging | completed | Phase 2 | 25 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06111560 | Exploring the Influence of Clinical Factors on the Prognosis of Papillary Renal Cell Carcinoma | completed | — | 160 | Sun Yat-sen UniversityOTHER | 0 | Nov 1, 2023 | clinicaltrials |
| NCT00617799 | Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma | completed | — | 15 | University of NebraskaOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT04534309 | Behavioral Weight Loss Program for Cancer Survivors in Maryland(ASPIRE) | completed | N/A | 340 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT00003102 | Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer | completed | Phase 1 / Phase 2 | 15 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT03680521 | Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma | completed | Phase 2 | 25 | Mirati Therapeutics Inc.INDUSTRY | 1 | Oct 4, 2023 | clinicaltrials |
| NCT06055660 | Moesin Expression in Clear Cell Renal Cell Carcinoma | completed | — | 50 | Sohag UniversityOTHER | 0 | Sep 28, 2023 | clinicaltrials |
| NCT01517243 | Phase II Study of Alternating Sunitinib and Temsirolimus | completed | Phase 2 | 37 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT02386826 | INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme | completed | Phase 1 | 65 | SCRI Development Innovations, LLCOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03207347 | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | completed | Phase 2 | 37 | University of FloridaOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT03200717 | Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment(IO-PAZ) | completed | Phase 2 | 62 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 21, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jun 18, 2024source: clinicaltrials